
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is well-positioned for long-term growth due to its strong data points, efficient business mix, and focus on late-stage clinical trials. However, potential ESG challenges and margin fluctuations may pose risks to the company's financial performance. Overall, with positive commercial momentum and potential for a rebound in margins, the outlook for Icon's stock is positive.
Bears say
Icon is a global contract research organization that has shown strong commitments to sustainability and environmental targets, leading to an above-average score from organizations like CDP and EcoVadis. However, the company has seen a decline in revenue and margins, with a projected adj. EBITDA margin of 16.5% and an estimated 4% organic revenue contraction in 2026 compared to 2025. Management has also indicated that they expect a similar progression throughout the rest of 2026 and that a significant amount of business is typically awarded in the days leading up to a quarter end. Additionally, the divestiture of Symphony Health and a new focus on targeted capital allocation and portfolio optimization may signal a shift in the company's strategic direction.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares